Page 9 - Beckley Psytech News Today

The Week In Psychedelics Last week saw some interesting developments from two of the largest publicly-traded companies in the psychedelics space:...

Beckley Psytech announces first cohort of psychotherapists have begun training for treatment resistant depression Phase 2 trials Training programme to be conducted in partnership with industry-leading educational company, FluenceInitiation of training represents key step to incorporate psychedelic-assisted psyc...

Beckley Psytech leads a new project focused on addressing  psychiatric and neurological conditions through the use of psychedelic medicines. - News - PharmaTimes

Almost one third of patients with cluster headache experience childhood onset but are not diagnosed until they are adults, new research shows.

Press release content from Business Wire. The AP news staff was not involved in its creation.

Woodstock, NY (PRWEB) November 04, 2021 -- Today, psychedelic therapy training provider Fluence announced the first close of its initial investment round with

Beckley Psytech, a privately owned, clinical stage, biotechnology company dedicated to addressing neuropsychiatric disorders through the novel application of psychedelic medicines, has today announced

Amanda Feilding, 78, is on a mission to explore the new frontier of pharmaceutical research: the health benefits of psychedelic substances

Smith says he’s done with making his life about gathering things, focusing now on giving them away.

Smith says he’s done with making his life about gathering things, focusing now on giving them away.